Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 6Gynecologic 4Gastrointestinal 4Thoracic 1Sarcoma 1Genitourinary 1

Conditions

Pancreatic Neoplasms 2Stomach Neoplasms 1Peritoneal Neoplasms 1Neoplasms by Site 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × genexol-PM × Gastrointestinal × Clear all
NCT03618758 2023-12-05

IPLUS

Seoul National University Bundang Hospital

Phase 1/2 Completed
35 enrolled
GastrointestinalGynecologic

Peritoneal Neoplasms, Stomach Neoplasms

NCT03008512 2021-02-04

A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib

Gachon University Gil Medical Center

Phase 2 Terminated
5 enrolled
Gastrointestinal

Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms by Site

NCT00882973 2017-05-05

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Samyang Biopharmaceuticals Corporation

Phase 1 Completed
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00111904 2011-12-14

Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡